Expertise in
4
conditions

Susana M. Cedres

Barcelona, CT, ES 
Expertise in
4
conditions
Barcelona, CT, ES 

Overview

Susana Cedres practices practicing medicine in Barcelona, Spain.

Ms. Cedres is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Mesothelioma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC).

She is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Barcelona, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
A Phase II Single Arm Clinical Trial Assessing the Efficacy and Safety of BIntrafusp Alfa (M7824) in Previously Treated Advanced Malignant Pleural MESothelioma (BIMES)
Enrollment Status: Completed
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations
Enrollment Status: Terminated
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
View 2 Less Clinical Trials

51 Total Publications

Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.
Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.
Journal: EJNMMI research
Published: December 05, 2025

Frequently Asked Questions about Susana M. Cedres

Is Susana M. Cedres a top-rated expert for Mesothelioma?

MediFind is an objective health platform that identifies experts based on real-world data. Susana M. Cedres is classified as an Elite expert for Mesothelioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Susana M. Cedres participate in research or clinical trials?

Yes. Susana M. Cedres has published 51 articles and abstracts on conditions like Mesothelioma. You can view a list of Susana M. Cedres's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Cedres's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile